Bernstein raises BeiGene stock price target to $259

On Thursday, Bernstein SocGen Group updated its outlook on BeiGene Ltd. (NASDAQ:ONC) (NASDAQ:BGNE) stock, increasing the price target to $259 from the previous $207, while maintaining a Market Perform rating. Currently trading at $249.12, BeiGene has demonstrated strong momentum with a 26% gain over the past six months. According to InvestingPro data, analyst targets for the stock range from $259 to $393, suggesting potential upside. The adjustment follows a detailed review of the company’s earnings and market potential, particularly focusing on the prospects of BeiGene’s pipeline drugs.

Analysts at Bernstein highlighted the increased competitive edge of sonrotoclax, a BCL-2 inhibitor, which they now see as a superior fixed duration therapy compared to the standard of care, venetoclax combined with obinutuzumab. This has led to a substantial revision of the peak sales estimate for sonrotoclax, doubling it to $1.9 billion from the initial $900 million forecast.

Additionally, the firm’s analysts are optimistic about the early stage data for BGB-16673 (BTK CDAC), a BTK PROTAC class drug. With the commencement of a head-to-head trial against pirtobrutinib, market share assumptions for BGB-16673 have been increased, with expectations of it capturing 68% of the market within its class. This is coupled with a higher probability of success assigned to the drug’s development and market penetration. The company’s impressive gross profit margin of 84.4% and strong revenue growth of 55% in the last twelve months support its research and development capabilities. InvestingPro subscribers can access 12 additional key metrics and insights about BeiGene’s financial health.

In terms of financial health, Bernstein revised BeiGene’s operational margin assumptions, acknowledging the company’s improved financial discipline and operational efficiency. They now expect BeiGene to reach profitability by 2025. However, the long-term forecasts for operating margins have been adjusted downwards from the mid-30s to the high-20s percentage range to better reflect the industry average.

The analyst’s comments provided a more detailed perspective on the rationale behind the price target increase: "Following our post-earnings Quick Take, we raise our price target for BeiGene from US $207 to US$259 based on the following key changes: Asset and market model updates and Margin updates."

BeiGene’s stock price target adjustment by Bernstein represents a significant vote of confidence in the company’s pipeline assets and its strategic direction. The updated estimates and forecasts reflect the potential impact of BeiGene’s product candidates on the market and the firm’s anticipated financial performance in the coming years. Based on InvestingPro Fair Value analysis, the stock is currently trading near its fair value, with analysts projecting profitability this year. The company maintains a moderate debt level with a debt-to-equity ratio of 0.32, positioning it well for future growth opportunities.

In other recent news, BeiGene Ltd. reported impressive fourth-quarter earnings, with total revenues reaching $1.1 billion, surpassing both company and consensus estimates. The strong performance was largely driven by Brukinsa, which achieved global sales of $828 million, exceeding expectations from firms like Guggenheim and Citizens JMP. Additionally, BeiGene received FDA Orphan Drug Designation for its drug sonrotocla, aimed at treating myelodysplastic syndromes, marking a significant milestone in its drug development efforts.

Analyst firms have responded positively to BeiGene’s achievements. BofA Securities upgraded the stock from Neutral to Buy, raising the price target to $320, reflecting confidence in Brukinsa’s sales growth. JPMorgan maintained its Overweight rating, citing optimism in BeiGene’s product pipeline, including the CDK4 inhibitor. Guggenheim and Citizens JMP both raised their price targets to $348, maintaining their Buy and Market Outperform ratings, respectively, due to the strong sales figures and future revenue forecasts.

BeiGene’s financial outlook for 2025 appears promising, with projected revenues between $4.9 billion and $5.3 billion, a significant increase from previous estimates. This optimistic forecast includes expectations of Brukinsa generating approximately $3.7 billion in sales. The company’s robust cash position of $2.6 billion further supports its growth trajectory in the biotech industry.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.